JLE

Hématologie

MENU

Acalabrutinib : une véritable avancée pour la prise en charge de la leucémie lymphoïde chronique en rechute ou réfractaire ? Volume 26, numéro 3, Mai-Juin 2020

  • [1] Byrd J.C., Brown J.R., O’Brien S. Ibrutinib versus Ofatumumab in previously treated chronic lymphoid leukemia. NEJM. 2014;371:213-223.
  • [2] Burger J.A., Tedeschi A., Barr P.M. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. NEJM. 2015;373:2425-2437.
  • [3] Byrd J.C., Wierda W.G., Schuh A. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia : updated phase 2 results. Blood. 2020;135:1204-1213.
  • [4] Long M., Beckwick K.A., Do P. Ibrutinib represents a novel class of immune modulating therapeutics that enhances the survival of activated T cells in vitro and in vivo through a non-BTK mediated mechanism. Blood. 2016;128. 22Abstract 3238